Proto Labs, Inc. logo PRLB - Proto Labs, Inc.

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY
0
BUY 6
HOLD 11
SELL 0
STRONG
SELL
0
| PRICE TARGET: $87.00 DETAILS
HIGH: $87.00
LOW: $87.00
MEDIAN: $87.00
CONSENSUS: $87.00
UPSIDE: 12.11%
AlphaVal

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 50% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Overvalued Strong
Trading 113.1% above fair value
Current Price $77.60
Bear Case $30.59 60.6% downside ($30.59 - $77.60) / $77.60 = -60.6% 4% stage 1 growth, 12% discount
Fair Value $36.41 53.1% downside ($36.41 - $77.60) / $77.60 = -53.1% 7% stage 1 growth, 12% discount
Bull Case $41.71 46.2% downside ($41.71 - $77.60) / $77.60 = -46.2% 9% stage 1 growth, 12% discount

Adjust Assumptions

7.3%
12.0%
3.0%

Key Value Driver

FCF growth rate (7% base case)

Terminal Value % of EV 32%
Implied Market Multiple 36.0x
Market is pricing in (growth) 18.8% vs our 7.3% base

Plain-Language Summary

Using a two-stage FCF DCF with 7% growth decelerating over 15 years, discounted at 12%, the base-case intrinsic value is $36.41 per share.

Analyst Consensus (External Reference)

Never blended into the bear/base/bull estimates above -- shown only as an outside comparison.

Average Target (17 analysts) $87.00
Analyst Range $87.00 – $87.00
Divergence from AlphaVal 58%

Warnings

Stock-based employee pay equals 74% of profits. This dilutes existing shareholders, so cash flow alone overstates what owners really earn.
Wall Street's average price target is $87.00 (from 17 analysts). Our estimate is 58% below the consensus -- consider that gap carefully.

Key Risks

  • P/E alone misleads — earnings depressed by growth investment
  • Cyclical or commodity businesses may be misclassified as platforms
  • Terminal value dominance suggests sensitivity to long-run assumptions